Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Robert Carruthers

Showing results (11-20 of 55) with videos related to

Pageof 6
Sort By:
Multiple Sclerosis and Related Disorders|March 24, 2021
Corpus callosum lesions are not inextricably linked to CNS symptoms in reported cases of susac syndromeGillian R Paton, Claire Sheldon, Talia Vertinsky, et al.
Multiple Sclerosis Journal - Experimental, Translational and Clinical|October 10, 2024
Cesarian sections in women with multiple sclerosis: A Canadian prospective pregnancy studyDessa Sadovnick, Maria Criscuoli, Irene Yee, et al.
Multiple Sclerosis Journal - Experimental, Translational and Clinical|March 26, 2026
Rescue cyclophosphamide for severe multiple sclerosis relapsesVlad C Bibic, Robert Carruthers, Daniel Hong, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|March 7, 2020
Adherence to laboratory monitoring among people taking oral drugs for multiple sclerosis: A Canadian population-based studyHuah Shin Ng, Elaine Kingwell, Feng Zhu, et al.
The Journal of Neuroscience : the Official Journal of the Society for Neuroscience|April 13, 2007
Biochemical and behavioral evidence for antidepressant-like effects of 5-HT6 receptor stimulationPer Svenningsson, Eleni T Tzavara, Hongshi Qi, et al.
Multiple Sclerosis and Related Disorders|July 24, 2018
Use of the new oral disease-modifying therapies for multiple sclerosis in British Columbia, Canada: the first five-yearsSolmaz Setayeshgar, Elaine Kingwell, Feng Zhu, et al.
Multiple Sclerosis and Related Disorders|November 27, 2018
Persistence and adherence to the new oral disease-modifying therapies for multiple sclerosis: A population-based studySolmaz Setayeshgar, Elaine Kingwell, Feng Zhu, et al.
Expert Opinion on Drug Safety|December 21, 2020
Short-term laboratory and related safety outcomes for the multiple sclerosis oral disease-modifying therapies: an observational studyElaine Kingwell, Tingting Zhang, Feng Zhu, et al.
Frontiers in Neurology|June 12, 2023
Accounting for uncertainty in training data to improve machine learning performance in predicting new disease activity in early multiple sclerosisMaryam Tayyab, Luanne M Metz, David K B Li, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|December 20, 2015
Children of chronically ill parents: Relationship between parental multiple sclerosis and childhood developmental healthNeda Razaz, K S Joseph, W Thomas Boyce, et al.
Pageof 6

Showing results (11-20 of 55) with videos related to

Sort By:
Pageof 6
Multiple Sclerosis and Related Disorders|March 24, 2021
Corpus callosum lesions are not inextricably linked to CNS symptoms in reported cases of susac syndromeGillian R Paton, Claire Sheldon, Talia Vertinsky, et al.
Multiple Sclerosis Journal - Experimental, Translational and Clinical|October 10, 2024
Cesarian sections in women with multiple sclerosis: A Canadian prospective pregnancy studyDessa Sadovnick, Maria Criscuoli, Irene Yee, et al.
Multiple Sclerosis Journal - Experimental, Translational and Clinical|March 26, 2026
Rescue cyclophosphamide for severe multiple sclerosis relapsesVlad C Bibic, Robert Carruthers, Daniel Hong, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|March 7, 2020
Adherence to laboratory monitoring among people taking oral drugs for multiple sclerosis: A Canadian population-based studyHuah Shin Ng, Elaine Kingwell, Feng Zhu, et al.
The Journal of Neuroscience : the Official Journal of the Society for Neuroscience|April 13, 2007
Biochemical and behavioral evidence for antidepressant-like effects of 5-HT6 receptor stimulationPer Svenningsson, Eleni T Tzavara, Hongshi Qi, et al.
Multiple Sclerosis and Related Disorders|July 24, 2018
Use of the new oral disease-modifying therapies for multiple sclerosis in British Columbia, Canada: the first five-yearsSolmaz Setayeshgar, Elaine Kingwell, Feng Zhu, et al.
Multiple Sclerosis and Related Disorders|November 27, 2018
Persistence and adherence to the new oral disease-modifying therapies for multiple sclerosis: A population-based studySolmaz Setayeshgar, Elaine Kingwell, Feng Zhu, et al.
Expert Opinion on Drug Safety|December 21, 2020
Short-term laboratory and related safety outcomes for the multiple sclerosis oral disease-modifying therapies: an observational studyElaine Kingwell, Tingting Zhang, Feng Zhu, et al.
Frontiers in Neurology|June 12, 2023
Accounting for uncertainty in training data to improve machine learning performance in predicting new disease activity in early multiple sclerosisMaryam Tayyab, Luanne M Metz, David K B Li, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|December 20, 2015
Children of chronically ill parents: Relationship between parental multiple sclerosis and childhood developmental healthNeda Razaz, K S Joseph, W Thomas Boyce, et al.
Pageof 6